Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

If a progression-free survival readout later this year is positive, the firm will pursue approval in HLA-A2-negative metastatic uveal melanoma.

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.

The regulator is allowing the firm to submit data on 4D-150 from a single Phase III trial and draw on readouts from previously conducted studies in wet AMD.

The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.

In a retrospective analysis of patients who received peptide vaccines via n-of-1 programs, 89 percent had immune reactions.

NEW YORK – A first-in-human Phase I trial is underway testing Atavistik Bio's ATV-1601 in patients with AKT1 E17K-mutated solid tumors, the Cambridge, Massachusetts-based company announced this week.

NEW YORK – Xoma Royalty on Monday said it will acquire Lava Therapeutics and discontinue developing its lead leukemia treatment candidate LAVA-1266, a CD123-targeted bispecific gamma delta T-cell ...